Modified PYY3-36 Analogue for Longer Half-Life and NPY2 Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing PYY3-36 analogues have short half-lives, requiring daily administration and lack sufficient NPY2 receptor selectivity and excitatory activity, necessitating improved formulations for enhanced therapeutic efficacy in weight regulation.
Innovation Solution
Development of chemically modified PYY3-36 analogues with fatty acid side chains and non-natural amino acids to stabilize the peptide structure, enhancing albumin binding and prolonging action time, while increasing NPY2 receptor selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If PYY3-36 is administered to exert therapeutic effect, then appetite suppression and weight loss are achieved, but the short half-life requires daily administration
Solution Approach 1:
The patent modifies the amino acid sequence of PYY3-36 by substituting specific residues (e.g., position 31, 32, 33, 34, 35, 36) to create analogues with altered pharmacokinetic properties. These sequence modifications increase plasma half-life from 10-15 minutes to potentially several hours, enabling less frequent dosing while maintaining appetite suppression and weight loss efficacy.
Solution Approach 2:
The patent creates hybrid peptide structures by combining PYY3-36 with other peptide sequences or modifying existing residues to form composite molecules. These composite analogues integrate the appetite-suppressing properties of PYY3-36 with extended half-life characteristics, reducing the need for daily administration.
2Reliability
If conventional PYY3-36 analogues are used, then some therapeutic effect is achieved, but NPY2 receptor selectivity and excitatory activity are insufficient
Solution Approach 1:
The patent applies local sequence modifications at specific positions within the PYY3-36 molecule to enhance NPY2 receptor binding affinity and selectivity. By targeting particular amino acid residues (such as positions 28-36) with conservative substitutions, the analogue achieves improved receptor selectivity without compromising overall therapeutic efficacy, enabling more reliable appetite suppression and weight loss.
Data Source
Figure 1a
Figure 1b~2
AI summary
The present application relates to the pharmaceutical field, and specifically provides a novel peptide tyrosine-tyrosine (PYY3-36) analogue or its salt or solvate, comprising a sequence structure of the following general formula (I): P-K-P-E-ψ-P-E-X10-D-X12-S-P-E-E-W-Q-R-Y-Y-X22-X23-L-R-H-Y-L-N- W-L-T-R-Q-R-Y-R1 (I). The novel peptide YY analogue (PYY3-36) provided by the present application has better pharmacological effects, longer action time, excellent bioavailability and safety.